Belgian neurotech ReVision Implant raises €4M for brain implant to restore sight

What's the deal? ReVision ImplantDealroom has a profile for this one. Try Dealroom →, a Belgian neurotech startup, has raised €4M (roughly $4.5M) to develop a brain implant designed to restore vision in severely blind patients. The company is building a cortical visual prosthesis — a device that bypasses damaged eyes entirely and stimulates the brain's visual cortex directly.

Why now? Advances in neurotechnology and brain-computer interfaces have accelerated in recent years, with companies like Neuralink pushing the field into the mainstream. ReVision Implant is riding that wave but targeting a specific medical need: helping patients for whom conventional treatments like retinal implants aren't an option.

What could go wrong? Brain implants face steep regulatory hurdles and long timelines to clinical use. The technology must prove both safe and effective in human trials, and commercialising neurostimulation devices for a relatively small patient population is notoriously difficult. Competing approaches and limited reimbursement pathways add further risk.

The signal: ReVision Implant's €4M raise underscores a broadening of neurotech investment beyond consumer-facing brain-computer interfaces. While late-growth players like Neuralink dominate headlines, early-growth companies targeting specific clinical applications — such as cortical visual prosthetics for severe blindness — are carving out a distinct funding lane. It's a sign that investors are willing to back long-horizon medtech bets where the science is maturing and unmet patient need is clear.

Read more: htworld.co.uk